embecta names new Chairman of the Board and Lead Independent Director

PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the “Board”) of embecta has elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately.

GlobeNewsWire • Feb 11, 2026

3 Healthcare Stocks Paying the Highest Dividends of 2026

Despite an 8.2% forward yield, be careful with Perrigo, due to its value trap reputation. Yielding 6.7%, Pfizer is a strong choice among high-yield dividend stocks, given the company's post-COVID-19 catalysts.

The Motley Fool • Feb 6, 2026

Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript

Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript

Seeking Alpha • Feb 5, 2026

Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results.

GlobeNewsWire • Feb 5, 2026

embecta Announces Quarterly Cash Dividend

PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.

GlobeNewsWire • Feb 5, 2026

embecta to Report Fiscal First Quarter Financial Results

PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026.

GlobeNewsWire • Jan 22, 2026

Embecta Corp. (EMBC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Embecta Corp. (EMBC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

embecta to Participate at the J.P. Morgan 2026 Healthcare Conference

PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P.

GlobeNewsWire • Dec 18, 2025

Embecta Growth Stalls Despite Strong Fiscal 2025 Results (Rating Downgrade)

Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold rating.

Seeking Alpha • Nov 29, 2025

Meet 33 Ideal "Safer" November Small/MidCap Value DiviBuys Of The S&P600

The S&P 600 Small/MidCap index offers high-yield dividend opportunities, with 33 out of 53 top-yielding stocks meeting both the 'safer' and IDEAL dividend Dogcatcher criteria. Top ten S&P600 dividend 'dogs' are projected to deliver 24% to 93% net gains by November 2026, based on analyst targets and current yields. Stocks like KNTK, SM, CRGY, and DEI stand out for strong total return potential, but investors should beware of negative free cash flow in some high-yield picks.

Seeking Alpha • Nov 26, 2025